Olpasiran

DB19001InvestigationalGene Therapies

Olpasiran is under investigation in clinical trial NCT05581303 (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (Ocean(a)) - Outcomes Trial).

Mechanism: Pharmacologically active on Apolipoprotein(a)
Curator reviewed
Also known as: ALL-P-AMBO-5'-O-((25S,30S)-39-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)-25,30-BIS((2-(2-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)ETHOXY)ETHYL)CARBAMOYL)-1,23,28,33-TETRAOXO-1-SULFANYL-2,5,8,11,14,17,20,37-OCTAOXA-24,29,34-TRIAZA-1.L
Code names: AMG-890

Resolves to

Compound

UNII8M4GC1EOB4CAS2225856-03-9

Targets

P08519LPA

What you can answer from here — as of September 19, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Olpasiran, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account